

The Impact of Normal Aging Out on Continuity of Treatment among Children and Adolescents Living with HIV in the PEPFAR Supported Program in Kenya

Authors: Lydia Odero^{1*}, Aaron Chafetz², Mary Gikura³, Deborah Goldstein², Rachel Golin², Diana Kemunto¹, Nelly Maina⁴, Immaculate Mutisya⁵, Kennedy Muthoka³, Evelyn Nganga¹, Tishina Okegbe⁴, Salome Okutoyi¹, Gonza Omoro⁶, George Siberry², Rose Wafula⁷, Dunstan Achwoka¹

¹ United States Agency for International Development (USAID), Nairobi, Kenya

² Office of HIV/AIDS, United States Agency for International Development (USAID), Washington, DC, USA

³ Palladium Kenya, Nairobi, Kenya

⁴ GHTASC, Credence Management Solutions LLC, supporting United States Agency for International Development (USAID), Office of HIV/AIDS, Washington, DC, USA

⁵ U.S. Centres for Disease Control (CDC), Nairobi, Kenya

⁶ U.S. Department of Defense, Nairobi, Kenya

⁷ National AIDS and STI Control Programme (NASCO), Nairobi, Kenya

* Corresponding author

Email: loderol@usaid.gov (LO)

1 **Abstract**

2 **Introduction:** To reduce HIV-related morbidity and mortality among children and adolescents
3 living with HIV, defined as those 0-14 years old, continuity of treatment is critical. Treatment
4 continuity estimates among children and adolescents living with HIV lag adults. We sought to
5 understand how aging out among children and adolescents living with HIV in Kenya impacts
6 continuity of treatment.

7
8 **Methods:** A retrospective cohort analysis was performed on de-identified individual-level data
9 from the Kenya National Data Warehouse for all clients who initiated and/or received antiretroviral
10 therapy between the periods of Oct 1, 2018 and Sep 30, 2022 (US Government fiscal years 2019-
11 2022). Children and adolescents living with HIV previously on antiretroviral therapy and those
12 newly initiating antiretroviral therapy were included in the analysis. Outcomes included aging out
13 of the cohort after turning 15 years old, interruption in treatment, return to treatment, and remaining
14 active on treatment.

15
16 **Results:** The study analyzed client-level data for four US Government fiscal years 2019-2022.
17 The number of active children and adolescents living with HIV on treatment at the end of fiscal
18 year 2019 was 44,628. This changed to 48,218, 48,262, and 44,780 representing 8%, 0%, and -7%
19 cohort growth/loss at the end of fiscal years 2020, 2021 and 2022, respectively. Among those who
20 were on treatment at the beginning of each fiscal year, aging-out accounted for 47%, 39%, and
21 28% of the total losses for the periods 2020, 2021 and 2022, respectively. Interruptions in treatment
22 accounted for proportions ranging from 5-9% among those active on treatment. Among the newly-
23 initiated on treatment within each fiscal year, aging-out proportions ranged from 3%-5%. Among

24 those who returned to treatment in each fiscal year, the proportions who remained active at the end
25 of the fiscal year varied from 72%-76%.

26

27 **Conclusions:** This analysis suggests that normal aging-out results in underestimation of HIV
28 treatment continuity for children and adolescents living with HIV. Routine aging out analyses can
29 inform programs on their true rates of interruptions in treatment, as they work to achieve epidemic
30 control among children and adolescents living with HIV.

31

32 **Key words:** Adolescents, Aging-out, HIV, HIV care continuum, Care and Treatment, Pediatrics

33 **Introduction**

34 Despite the “Treat All” era, pediatric antiretroviral therapy (ART) coverage remains well-below
35 adult coverage, with 63% ART coverage rates for children and adolescents living with HIV
36 (C/ALHIV) (0-14 years) in Eastern and Southern Africa compared to 83% for adults (≥ 15 years)
37 [1]. Only 70% of C/ALHIV in the region have a known HIV status, and of those receiving ART,
38 only 51% are virally suppressed [2]. These dire statistics are attributed in part to inadequate
39 antenatal care to prevent vertical transmission, poor retention in care among pregnant women with
40 HIV, and the rate of HIV infection among children while breastfeeding [3]. Poor viral load
41 suppression (VLS) and interruptions in treatment (IIT) among C/ALHIV has been associated with
42 among others, difficult to take ART formulations; history of opportunistic infections; and
43 caregiver’s VLS status and household vulnerability [4-8].

44

45 Optimized case-finding and enhanced linkage to treatment are needed to close gaps in ART
46 coverage and HIV-related morbidity and mortality for C/ALHIV [9]. While HIV continuity of
47 treatment (CoT) is essential for VLS, prevention of disease progression and mortality, and further
48 transmission; data is limited on impact of aging on CoT proxies used for programmatic evaluation
49 and improvement.

50
51 Tanzanian program data revealed substantial loss in the number of C/ALHIV on ART in 2015.
52 Subsequently, systematic retrospective analysis led to development of a standardized tool for loss
53 analyses for those aged 0-14 years (unpublished program data). This tool was refined in 2019,
54 when the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) instituted IIT reporting.
55 Included were C/ALHIV who had: - transferred out of a clinical site; refused or stopped ART;
56 experienced IIT; and died [10]. These site-level data provided granular assessment of C/ALHIV
57 experiencing IIT and were used to optimize CoT and achieve VLS.

58
59 In 2021, PEPFAR advised programs to routinely review adolescent fine age bands to identify
60 ongoing gaps in CoT and VLS [11]. Since 2022, PEPFAR guidance has encouraged programs to
61 evaluate electronic medical records (EMRs) and person-based registries to assess actual experience
62 of aging out in pediatric cohorts [12-13]. However, because PEPFAR's data is reported at
63 aggregate and not individual-level, analysis of CoT follows the same and does not correctly
64 account for clients who 'age out' during transitions between fiscal years (FY).

65
66 Analysis of PEPFAR data from 2018-2019 in eight African countries showed that aging can distort
67 age-band retention estimates [14]. This study used 1-year age-bands from 2018 SPECTRUM

68 modeling data to adjust for aging and reported that the adjustment increased ART retention
69 estimates for those aged <1 and 1-9 years but had variable effects on retention for 10-14 and 15-
70 19 years. Authors recommended country-specific analysis to better understand implications of
71 ‘aging out’ for these age bands and better optimize C/ALHIV CoT [14]. In Tanzania, the USAID
72 Afya Yangu Northern project reported that in FY2022, aging out contributed to 48% of the loss in
73 current on ART among C/ALHIV and adjustment for aging out improved pediatric proxy retention
74 from 86% to 96% and program growth from -2% to 10% (unpublished data). Additionally,
75 retrospective cohort analysis of C/ALHIV on ART in Kenyan USAID-supported facilities from
76 2019-2020 showed that normal aging results in underestimated CoT rates [15].

77
78 Compared to aggregate-level data, individual-level data presents a better platform to describe the
79 aging effect among clients on treatment. Evolution of EMRs and establishment of the Kenya
80 National Data Warehouse (NDW) provides such an opportunity [16]. This analysis utilizes
81 individual-level data from the NDW to understand how C/ALHIV aging-out impacts CoT in
82 Kenya.

83 **Methods**

84 **Study Design**

85 The study employed a retrospective cohort observational design to investigate aging out and
86 treatment interruptions among C/ALHIV on treatment. The analysis included all clients 0-14 years
87 old at any time period between October 1, 2018, and September 30, 2022 [FY2019 – FY2022])
88 and were either newly initiated on ART or currently on ART during the same period.

89

90 **Materials or Instruments & Data Collection**

91 De-identified client records were accessed from the National Data Warehouse (NDW) on April
92 18, 2023, and extracted for analysis. NDW is a repository of de-identified individual-level client
93 data offered care and treatment services at health facilities. Facility-based health-care workers use
94 the Ministry of Health comprehensive care clinic card (MOH 257) to document clinical notes for
95 clients either newly initiating ART or attending subsequent clinical visits. This tool/card is
96 digitized in the facility EMR system. De-identified data from the facility EMR is then transmitted
97 to the NDW monthly. The authors did not have information that could identify individual clients
98 during or after data collection. RStudio version 2022.12.0 was used for the analysis.

99 **Variables**

100 Data were extracted from the NDW using the following variables: facility name, master facility
101 listing code, client ID, date of birth, sex, ART initiation date, ART regimen at initiation, current
102 ART regimen, appointment and visit dates. Using client's appointment and visit dates, the
103 outcomes below were computed per FY:

- 104 1) Aged out - a client who turns 15 years old before or at the end of FY.
- 105 2) IIT - a client with no clinical contact for 28 days after their last scheduled appointment or
106 expected clinical contact.
- 107 3) Return to treatment - a client who experienced IIT during any previous FYs, who
108 successfully reinitiated ART within the FY of interest and remained on treatment until the
109 end of that FY.
- 110 4) Active on treatment - a client who is currently receiving ART within a FY and remained
111 on ART as at the end of the FY.

112 5) Unclassified - a category for clients who do not fit into any of the defined categories
113 mentioned above.

114 **Data Analysis**

115 Data analysis involved a multi-step approach to longitudinal data on clients' status across multiple
116 FYs with data cleaning and quality control procedures to eliminate irrelevant or incomplete
117 records. The dataset was then grouped according to client identifiers and FYs; and aggregation
118 techniques were employed to calculate counts of clients into various outcome categories for each
119 FY. Descriptive techniques were used to summarize and present the data's key features. A Sankey
120 diagram was used to present visualization of clients' movement from one outcome category at the
121 beginning or in the course of a given FY to another category at the end of the same FY.

122 **Ethical Considerations**

123 The research was approved by Jomo Kenyatta University of Agriculture and Technology, Ethics
124 and Research Committee (JKU/ISERC/02316/0880); Office of the Associate Director for Science,
125 Centers for Disease Control and Prevention (CDC) with Accession #: CGH-KEN-1/18/23-8faf7;
126 and research license obtained from the National Commission for Science, Technology &
127 Innovation (NACOSTI/P/23/27455). Client's consent was not required as the authors neither
128 interacted with the clients nor had access to identifiable data.

129 **Results**

130 Clinical records of C/ALHIV on treatment or initiating treatment in the Kenyan NDW were
131 analyzed for a period of four FYs 2019-2022. At the end of FY2019, 44,628 (72.7%) C/ALHIV

132 remained on treatment. At the end of each of the FYs 2020, 2021, and 2022, 48,218 (78.6%),
 133 48,262 (78.7%) and 44,780 (73.0%) C/ALHIV remained active on treatment (Table 1).

Table 1: Kenya Children and Adolescent HIV Treatment Cohort, National Data Warehouse, Fiscal Years (FY) 2020 - 2022

	FY2020 (n= 61,357)	FY2021 (n=60,610)	FY2022 (n=55,166)
Status During Fiscal Year			
<i>Newly initiating ART</i>	5,183 (8.4%)	3,264 (5.4%)	2,047 (3.7%)
<i>Returned to Treatment</i>	3,841 (6.3%)	3,191 (5.3%)	2,118 (3.8%)
<i>Unclassified</i>	7,705 (12.6%)	5,942 (9.8%)	2,752 (5.0%)
<i>Current on Treatment (prior fiscal year)</i>	44,628 (72.7%)	48,213 (79.5%)	48,249 (87.5%)
Status End of Fiscal Year			
<i>Active on Treatment</i>	48,218 (78.6%)	48,262 (78.7%)	44,780 (73.0%)
<i>Interruptions in Treatment</i>	6,903 (11.3%)	5,430 (8.8%)	3,400 (5.5%)
<i>Aged Out</i>	5,603 (9.1%)	6,734 (11.0%)	6,986 (11.4%)
<i>Unclassified</i>	633 (1.0%)	184 (0.3%)	- (0.0%)
Loss/Gain (%)	3,590(8%)	49(0%)	-3,469 (-7%)

134
 135 Overall, the cohort grew by 3,590 (8%) in FY2020 and reduced by 3,469 (7%) by the end of FY
 136 2022. C/ALHIV who had disengaged from care and returned to treatment captured within the
 137 course of FYs 2020, 2021, and 2022 stood at 3,841 (6.3%), 3,191 (5.3%), and 2,118 (3.8%)
 138 respectively. The cohort of C/ALHIV interrupting treatment at the end of FY2020, FY2021 and
 139 FY2022 were 6,903 (11.3%), 5,430 (8.8%) and 3,400 (5.5%) while 5,603 (9.1%), 6,734 (11.0%)
 140 and 6,986 (11.4%) C/ALHIV aged out at the end of each of the respective FYs (Table 1).

141
 142 Over the four FYs from 2019-2022, 80% of C/ALHIV remained active on treatment among the
 143 current on treatment cohort (i.e. those who were already on treatment at the start of the FY). For
 144 this cohort, IIT stood at 4,187 (9%), 3,864 (8%), and 2,564 (5%) at the end of each of the three FY
 145 transitions. In FY2020, 4,698 (11%) of the current on treatment cohort aged out, while in FY2021
 146 and FY2022, 5,944 (12%) and 6,489 (13%) of the cohort aged out. IIT accounted for 53%, 61%
 147 and 72% of the total losses experienced in FY2020, FY2021 and FY2022 respectively. Losses
 148 attributed to aging out among clients currently on treatment were 47% in FY2020, 39% in FY21,
 149 and 28% in FY2022 (Table 2).

Table 2: Kenya C/ALHIV Aging Out Analysis (at end of FY2020, 2021 and 2022)

	FY2020	FY2021	FY2022
Among Active on Treatment (prior fiscal year)	(n= 44,628)	(n= 48,213)	(n= 48,249)
<i>Remained Active on Treatment (%)</i>	35,743 (80%)	38,405 (80%)	39,196 (81%)
<i>Interruptions in Treatment (IIT) (%)</i>	4,187 (9%)	3,864 (8%)	2,564 (5%)
<i>Aged Out (%)</i>	4,698 (11%)	5,944 (12%)	6,489 (13%)
<i>% Loss attributed to aging out</i>	47%	39%	28%
<i>% Loss attributed to IIT</i>	53%	61%	72%
Among Clients Newly Initiated on Treatment (current fiscal year)	(n= 5,183)	(n= 3,264)	(n=2,047)
<i>Remained Active on Treatment (%)</i>	3,353 (65%)	2,534 (78%)	1,721 (84%)
<i>Interruptions in Treatment (IIT) (%)</i>	1,048 (20%)	429 (13%)	233 (11%)
<i>Aged Out (%)</i>	149 (3%)	117 (4%)	93 (5%)
<i>Unclassified</i>	633	184	
Returned to Treatment	(n=3,841)	(n=3,191)	(n=2,118)

<i>Remained Active on Treatment (%)</i>	2,904 (76%)	2,294 (72%)	1,575 (74%)
<i>Interruptions in Treatment (IIT) (%)</i>	647 (17%)	646 (20%)	352 (17%)
<i>Aged Out (%)</i>	290 (8%)	251 (8%)	191 (9%)

150

151 Among C/ALHIV who newly initiated ART, 3,353 (65%), 2,534 (78%), and 1,721 (84%)
152 remained active across the three FY transitions into FY2020, FY2021, and FY2022, respectively.
153 IIT in this cohort stood at 1,048 (20%), 429 (13%), and 233 (11%) across the three FYs. Aging
154 out among C/ALHIV who newly initiated ART consisted of 149 (3%), 117 (4%) and 93 (5%)
155 clients across the three FY transitions.

156

157 Among the cohort of C/ALHIV who returned to treatment, those who remained active till end of
158 the FY consisted of 2,904 (76%), 2,294 (72%) and 1,575 (74%) across FY2020, FY2021 and
159 FY2022 respectively. IIT were 647 (17%), 646 (20%), 352 (17%) while aging out was 290 (8%),
160 251 (8%) and 191 (9%) for the three FYs (Table 2).

161

162 In 2020, 7,705 clients were in the unclassified category, making up 8% of the total. However, by
163 the end of 2020, this number dropped to 633 (92% decrease).

164

165 The movement of clients from one category to the other between fiscal years is depicted by the
166 Sankey diagrams as shown in Figs 1-3.

167

168 **Fig 1. Tracking treatment outcomes among C/ALHIV in Kenya – FY2019 - FY2020**

169 **Fig 2. Tracking treatment outcomes among C/ALHIV in Kenya – FY2020 - FY2021**

170 **Fig 3. Tracking treatment outcomes among C/ALHIV in Kenya – FY2021 - FY2022**

171 **Discussion**

172 Normal aging-out of the <15-year-old cohort comprises a significant source of cohort “loss”
173 among C/ALHIV continuing ART for each FY from 2020-2022 and is greater than IIT in both
174 FY2021 and FY2022. Impact of aging-out is not routinely captured in programmatic PEPFAR data
175 and requires individual-level data analysis for identification. In this analysis, impact of aging-out
176 results in CoT estimates that underestimate actual CoT for C/ALHIV. Additionally, C/ALHIV
177 who experienced IIT decreased each FY under study, perhaps due to successful programmatic
178 interventions such as Operation Triple Zero - a customized adolescent-focused service delivery
179 model for “Zero viral load, Zero missed appointments, and Zero missed drugs”, implemented
180 around the same timeframe [17].

181
182 When a C/ALHIV is not retained on ART, understanding IIT root causes allows for tailored CoT
183 interventions that improve clinical outcomes. Programs can then provide targeted support to
184 C/ALHIV on ART who have aged out of the cohort, but remain on treatment, to ensure successful
185 transition to adulthood. Focused, person-centered support is particularly important as
186 demonstrated through a recent systematic review that indicated wide variation (37 to 97.4%) of
187 CoT rates among ALHIV following transition to adult services [18].

188
189 Based on our analyses that allowed for accurate estimation of CoT, future directions would include
190 analyzing individual-level clinical outcomes among subsets of C/ALHIV who experienced IIT.
191 Analysis of IIT root causes among C/ALHIV at clinical sites will shed light on specific reasons
192 for ART interruption and provide actionable data to optimize program implementation.
193 Additionally, individual-level analyses are needed to verify if adolescents who aged out of

194 pediatric cohorts (0-14 years) have successfully transitioned to adult cohorts (15+ years). Kenya's
195 National Unique Patient Identifier program utilizes birth certificate registration numbers to provide
196 unique identifier numbers to C/ALHIV. Future Kenyan analyses can utilize these identifiers to
197 deduplicate and track outcomes of C/ALHIV who experience IIT.

198
199 This analysis has some limitations. Firstly, it excludes Kenyan treatment sites that utilize paper
200 records and sites in seven low-HIV burden counties potentially affecting generalizability of
201 findings. As of Jan 2022, 85% (1,046,761) of all clients on ART were seen at an EMR-site.
202 Secondly, annual analysis may mask short-term trends. And lastly, the study population focuses
203 on those with documented interruptions, omitting transfers and deaths.

204
205 “Aging Out” analyses are now easier to perform - EMRs are more prevalent; access to patient-
206 level data has increased; standardized protocols for loss analysis are refined; and PEPFAR
207 guidance is now explicit in calling for these analyses. However, performing these analyses
208 separately for each age-band and implementing partner remains burdensome. Ideally these
209 analyses would be performed through unified host country data systems that house patient-level
210 data reported directly to Ministries of Health (MoH), and MoH partners. This would permit speedy
211 identification of gaps in CoT, adjusting for losses and gains due to normal aging-out. Ultimately,
212 by improving individual-level clinical outcomes for C/ALHIV, these analyses bolster long-term
213 sustainability of host country HIV treatment programs.

214 **Conclusions**

215 This analysis suggests that normal aging-out results in underestimation of HIV treatment
216 continuity for C/ALHIV. Routine aging-out analyses can inform programs on their true rates of
217 IIT, as they work to achieve epidemic control among C/ALHIV.

218 **Acknowledgements**

219 We thank Nassir Kashmiri, formerly with Management and Development for Health (MDH),
220 Tanzania, and Roland Van de Ven, USAID Afya Yangu Northern, Tanzania, for sharing
221 unpublished data with the study authors, and Ohvia Muraleetharan who worked on the initial
222 abstract for this paper.

223 **References**

- 224 1. Joint United Nations Programme on HIV/AIDS. UNAIDS Data 2023 [Internet]. 2023 [cited
225 2023 Sep 22]. Available from: <https://aidsinfo.unaids.org>
- 226 2. UNICEF. Monitoring the situation of children and women [Internet]. 2023 [cited 2023 Oct
227 3]. Available from: <https://data.unicef.org/topic/hivaids/paediatric-treatment-and-care/>
- 228 3. Govender K, Nyamaruze P, Cowden RG, Pillay Y, Bekker LG. Children and young women
229 in eastern and southern Africa are key to meeting 2030 HIV targets: time to accelerate
230 action. *Lancet HIV* [Internet]. 2023;10(5):e343–50. Available from:
231 <https://www.sciencedirect.com/science/article/pii/S2352301823000127>
- 232 4. Afrane AKA, Goka BQ, Renner L, Yawson AE, Alhassan Y, Owiafe SN, Agyeman S,
233 Sagoe KWC, Kwara A. HIV virological non-suppression and its associated factors in
234 children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-
235 sectional study. *BMC Infect Dis*. 2021;21(1):731. doi: 10.1186/s12879-021-06459-z.
236 PMID: 34340689; PMCID: PMC8330060.
- 237 5. Tanyi WN, Gachuno O, Odero T, Farquhar C, Kimosop D, Mayi A. Factors affecting

- 238 adherence to antiretroviral therapy among children and adolescents living with HIV in the
239 Mbita Sub-County Hospital, Homa Bay- Kenya. *Afr Health Sci.* 2021;21(Suppl):18-24. doi:
240 10.4314/ahs.v21i1.4S. PMID: 34447419; PMCID: PMC8367307
- 241 6. Humphrey JM, Genberg BL, Keter A, Musick B, Apondi E, Gardner A, et al. Viral
242 suppression among children and their caregivers living with HIV in Western Kenya. *J Int*
243 *AIDS Soc.* 2019;22(4):e25272. doi: 10.1002/jia2.25272
- 244 7. Onyango B, Mokaya R, Wasianga J, Wao H, Achwoka D, Onyango N, Kadengye DT.
245 Factors associated with viral load suppression among orphans and vulnerable children and
246 adolescents living with HIV in Kenya. *PLOS global public health.* 2023;3(3), e0000794.
247 <https://doi.org/10.1371/journal.pgph.0000794>
- 248 8. Teasdale CA, Sogaula N, Yuengling KA, Wang C, Mutiti A, Arpadi S, et al. HIV viral
249 suppression and longevity among a cohort of children initiating antiretroviral therapy in
250 Eastern Cape, South Africa. *J Int AIDS Soc.* 2018;21(8):e25168. doi: 10.1002/jia2.25168
- 251 9. Rosen JG, Muraleetharan O, Walker A, Srivastava M. Pediatric Antiretroviral Therapy
252 Coverage and AIDS Deaths in the “Treat All” Era. *Pediatrics* [Internet]. 2023;151(6).
253 Available from: <https://doi.org/10.1542/peds.2022-05901>
- 254 10. PEPFAR. PEPFAR Monitoring, Evaluation, and Reporting Indicator Reference Guide:
255 MER 2.0 (Version 2.5) [Internet]. 2020 [cited 2023 May 19]. Available from:
256 [https://datim.zendesk.com/hc/article_attachments/360071630231/FY21_MER_2.5_Indicator](https://datim.zendesk.com/hc/article_attachments/360071630231/FY21_MER_2.5_Indicator_Reference_Guide.pdf)
257 [or_Reference_Guide.pdf](https://datim.zendesk.com/hc/article_attachments/360071630231/FY21_MER_2.5_Indicator_Reference_Guide.pdf)
- 258 11. PEPFAR. PEPFAR 2021 Country and Regional Operational Plan (COP/ROP) Guidance for
259 all PEPFAR Countries [Internet]. 2021 [cited 2023 May 22]. Available from:
260 <https://www.state.gov/wp-content/uploads/2020/12/PEPFAR-COP21-Guidance-Final.pdf>
- 261 12. PEPFAR. PEPFAR 2022 Country and Regional Operational Plan (COP/ROP) Guidance for
262 all PEPFAR-Supported Countries [Internet]. 2022 [cited 2023 May 16]. Available from:
263 [https://www.state.gov/wp-content/uploads/2022/02/COP22-Guidance-Final_508-](https://www.state.gov/wp-content/uploads/2022/02/COP22-Guidance-Final_508-Compliant-3.pdf)
264 [Compliant-3.pdf](https://www.state.gov/wp-content/uploads/2022/02/COP22-Guidance-Final_508-Compliant-3.pdf)
- 265 13. PEPFAR. PEPFAR FY 2024 Technical Considerations [Internet]. 2023 [cited 2023 May
266 22]. Available from: [https://www.state.gov/wp-content/uploads/2023/02/FY-2024-](https://www.state.gov/wp-content/uploads/2023/02/FY-2024-PEPFAR-Technical-Considerations.pdf)
267 [PEPFAR-Technical-Considerations.pdf](https://www.state.gov/wp-content/uploads/2023/02/FY-2024-PEPFAR-Technical-Considerations.pdf)
- 268 14. Stephens JL. Impact of Aging on ART Continuation for Performance Management and

- 269 Target Setting. In: Virtual Conference. CROI; 2021.
- 270 15. Odero L, Muraleetharan O, Simiyu T, Achwoka D, Golin R. How many adolescents do we
271 actually lose along the HIV treatment cascade?: Accounting for aging up in adolescent
272 continuity of treatment. In: Virtual Conference [Internet]. International Workshop on HIV
273 and Adolescence; 2021. Available from:
274 [https://academicmedicaleducation.com/meeting/international-workshop-hiv-adolescence-](https://academicmedicaleducation.com/meeting/international-workshop-hiv-adolescence-2021/e-poster/how-many-adolescents-do-we-actually)
275 [2021/e-poster/how-many-adolescents-do-we-actually](https://academicmedicaleducation.com/meeting/international-workshop-hiv-adolescence-2021/e-poster/how-many-adolescents-do-we-actually)
- 276 16. Ndisha M, Hassan AS, Ngari F, Munene E, Gikura M, Kimutai K, et al. Leveraging
277 electronic medical records for HIV testing, care, and treatment programming in Kenya—
278 the national data warehouse project. *BMC Med Inform Decis Mak* [Internet].
279 2023;23(1):183. Available from: <https://doi.org/10.1186/s12911-023-02265-6>
- 280 17. Centers for Disease Control and Prevention. Operation Triple Zero: Empowering
281 Adolescents and Young People living with HIV in Ethiopia [Internet]. CDC; 2021 [cited
282 2023 Oct 11]. Available from: [https://www.cdc.gov/globalhivtb/who-we-](https://www.cdc.gov/globalhivtb/who-we-are/features/operationtriplezero.html)
283 [are/features/operationtriplezero.html](https://www.cdc.gov/globalhivtb/who-we-are/features/operationtriplezero.html)
- 284 18. Ritchwood TD, Malo V, Jones C, Metzger IW, Atujuna M, Marcus R, et al. Healthcare
285 retention and clinical outcomes among adolescents living with HIV after transition from
286 pediatric to adult care: a systematic review. *BMC Public Health* [Internet].
287 2020;20(1):1195. Available from: <https://doi.org/10.1186/s12889-020-09312-1>




Fig 1. Tracking treatment outcomes among C/ALHIV in Kenya - FY




Fig 2. Tracking treatment outcomes among C/ALHIV in Kenya - FY




Fig 3. Tracking treatment outcomes among C/ALHIV in Kenya - FY